XML 22 R12.htm IDEA: XBRL DOCUMENT

Long-Term Investments

3 Months Ended

Mar. 31, 2023

5. LONG-TERM INVESTMENTS

(1)

The ownership percentages of each investee are listed as follows:

	Ownership percentage
	March 31,			December 31,			Accounting
Name of related party	2023			2022			treatments
Braingenesis Biotechnology Co., Ltd.		0.22	%		0.22	%	Cost Method
Genepharm Biotech Corporation		0.92	%		0.92	%	Cost Method
BioHopeKing Corporation		8.03	%		8.03	%	Cost Method
BioFirst Corporation		21.77	%		21.77	%	Equity Method
Rgene Corporation		28.85	%		28.85	%	Equity Method

(2)

The extent the investee relies on the company for its business are summarized as follows:

Name of related party		The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd.		No specific business relationship
Genepharm Biotech Corporation		No specific business relationship
BioHopeKing Corporation		Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation		Loaned from investee and provides research and development support service
Rgene Corporation		Collaborating with the Company to develop and commercialize drugs

(3)

Long-term investment mainly consists of the following:

	March 31, 2023		December 31, 2022
	(Unaudited)
Non-marketable Cost Method Investments, net
Braingenesis Biotechnology Co., Ltd.	$	7,235	$	7,169
Genepharm Biotech Corporation		22,089		21,887
BioHopeKing Corporation		820,519		813,014
Sub total		849,843		842,070
Equity Method Investments, net
BioFirst Corporation		-		-
Rgene Corporation		-		-
Total	$	849,843	$	842,070

(a)

BioFirst Corporation (the “BioFirst”):

The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of March 31, 2023 and December 31, 2022, the Company owns 21.77% and 21.77% common stock shares of BioFirst, respectively. The Company made prepayment for equity investment in BioFirst to purchase additional 317,000 shares to be issued by BioFirst in the aggregate amount of $623,856 and $618,150, recorded as prepayment for long-term investments as of March 31, 2023 and December 31, 2022, respectively.

Summarized financial information for the Company’s equity method investee, BioFirst, is as follows:

Balance Sheet

	March 31, 2023		December 31, 2022
	(Unaudited)
Current Assets	$	1,958,500	$	1,543,152
Non-current Assets		801,410		739,472
Current Liabilities		1,675,194		2,663,051
Non-current Liabilities		357,150		103,447
Stockholders’ Equity (Deficit)		727,566		(483,874	)

Statement of Operations

	Three months Ended March 31,
	2023			2022
	(Unaudited)
Net sales	$	-		$	8,808
Gross profit		-			6,133
Net loss		(406,233	)		(498,940	)
Share of losses from investments accounted for using the equity method		-

(b)	Rgene Corporation (the “Rgene”)

Both Rgene and the Company are under common control by Dr. Tsung-Shann Jiang, the CEO and Chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant influence, but not control, over the Rgene, the Company determined to use the equity method to account for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of March 31, 2023 and December 31, 2022, the Company owns 28.85% and 28.85% Common Stock shares of Rgene, respectively. On March 31, 2023, Dr. Tsung-Shann Jiang has been elected to become the Chairman of Rgene.

Summarized financial information for the Company’s equity method investee, Rgene, is as follows:

Balance Sheets

	March 31, 2023			December 31, 2022
	(Unaudited)
Current Assets	$	54,987		$	68,302
Noncurrent Assets		288,160			303,893
Current Liabilities		2,491,974			2,478,868
Noncurrent Liabilities		2,048			2,441
Shareholders’ Deficit		(2,150,875	)		(2,109,114	)

Statement of Operations

	Three months Ended March 31,
	2023			2022
	(Unaudited)
Net sales	$	-		$	-
Gross Profit		-			-
Net loss		(81,842	)		(149,480	)
Share of loss from investments accounted for using the equity method		-			-

(4)	Disposition of long-term investment

During the three months ended March 31, 2023 and 2022, there is no disposition of long-term investment.

(5)	Losses on Equity Investments

The components of losses on equity investments for each period were as follows:

		Three months Ended March 31,
		2023		2022
		(Unaudited)
Share of equity method investee losses	$	-	$	-